ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 141,46
-0,67%
Dow Jones
39 872,99
0,17%
DAX
18 726,76
-0,21%
Brent Oil
82,445
-1,30%
Bitcoin
69 819,00
-2,28%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Rhythm Pharmaceuticals Inc (RYTM)

  7. Rhythm Pharmaceuticals Inc (RYTM) Actualités

RYTM

Rhythm Pharmaceuticals (RYTM)

Rhythm Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RYTM
DateHeureSourceTitreSymboleSociété
13/05/202422h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RYTMRhythm Pharmaceuticals Inc
09/05/202422h17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RYTMRhythm Pharmaceuticals Inc
09/05/202422h01GlobeNewswire Inc.Rhythm Pharmaceuticals Announces New Employment Inducement GrantsNASDAQ:RYTMRhythm Pharmaceuticals Inc
07/05/202422h43Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RYTMRhythm Pharmaceuticals Inc
07/05/202413h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RYTMRhythm Pharmaceuticals Inc
07/05/202413h00GlobeNewswire Inc.Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business UpdateNASDAQ:RYTMRhythm Pharmaceuticals Inc
06/05/202414h00GlobeNewswire Inc.Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual MeetingNASDAQ:RYTMRhythm Pharmaceuticals Inc
30/04/202400h30GlobeNewswire Inc.Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & EndocrinologyNASDAQ:RYTMRhythm Pharmaceuticals Inc
24/04/202422h01GlobeNewswire Inc.Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024NASDAQ:RYTMRhythm Pharmaceuticals Inc
01/04/202414h00GlobeNewswire Inc.Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock FinancingNASDAQ:RYTMRhythm Pharmaceuticals Inc
25/03/202413h00GlobeNewswire Inc.Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific AgonistNASDAQ:RYTMRhythm Pharmaceuticals Inc
06/03/202422h01GlobeNewswire Inc.Rhythm Pharmaceuticals Announces Participation at Upcoming Investor ConferencesNASDAQ:RYTMRhythm Pharmaceuticals Inc
29/02/202422h58Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RYTMRhythm Pharmaceuticals Inc
29/02/202422h44Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RYTMRhythm Pharmaceuticals Inc
29/02/202422h05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RYTMRhythm Pharmaceuticals Inc
22/02/202413h01GlobeNewswire Inc.Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in JapanNASDAQ:RYTMRhythm Pharmaceuticals Inc
22/02/202413h00GlobeNewswire Inc.Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business UpdateNASDAQ:RYTMRhythm Pharmaceuticals Inc
07/02/202414h00GlobeNewswire Inc.Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl SyndromeNASDAQ:RYTMRhythm Pharmaceuticals Inc
31/01/202414h00GlobeNewswire Inc.Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024NASDAQ:RYTMRhythm Pharmaceuticals Inc
04/01/202413h00GlobeNewswire Inc.Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640NASDAQ:RYTMRhythm Pharmaceuticals Inc
04/01/202412h58GlobeNewswire Inc.Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional UpdatesNASDAQ:RYTMRhythm Pharmaceuticals Inc
13/12/202313h00GlobeNewswire Inc.Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023NASDAQ:RYTMRhythm Pharmaceuticals Inc
06/12/202313h00GlobeNewswire Inc.Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D EventNASDAQ:RYTMRhythm Pharmaceuticals Inc
07/11/202313h00GlobeNewswire Inc.Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business UpdateNASDAQ:RYTMRhythm Pharmaceuticals Inc
02/11/202313h00GlobeNewswire Inc.Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)NASDAQ:RYTMRhythm Pharmaceuticals Inc
25/10/202314h00GlobeNewswire Inc.Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023NASDAQ:RYTMRhythm Pharmaceuticals Inc
17/10/202322h01GlobeNewswire Inc.Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023NASDAQ:RYTMRhythm Pharmaceuticals Inc
10/10/202314h00GlobeNewswire Inc.Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®NASDAQ:RYTMRhythm Pharmaceuticals Inc
22/09/202314h00GlobeNewswire Inc.Rhythm Pharmaceuticals Presents New Data at ESPE 2023NASDAQ:RYTMRhythm Pharmaceuticals Inc
19/09/202314h01GlobeNewswire Inc.Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic ObesityNASDAQ:RYTMRhythm Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:RYTM

Dernières Valeurs Consultées

EU
RNO
Renault
NYSE
KO
Coca Cola
NASDAQ
AMZN
Amazon.com
EU
LR
Legrand
EU
GLE
Societe Generale
NYSE
NKE
Nike
EU
VK
Vallourec
EU
CS
Axa
NASDAQ
NVDA
NVIDIA
EU
VIV
Vivendi
EU
PX4
SBF 120
EU
BEL20
Bel 20
NASDAQ
AAPL
Apple
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés